Clinical trial
12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day…
NCT00456794 · Kyowa Kirin, Inc., Industry · Completed
Key facts
| NCT number | NCT00456794 |
|---|---|
| Title | 12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa |
| Official title | A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of Doses of 20 and 60 mg/Day Istradefylline as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa |
| Lead sponsor | Kyowa Kirin, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug |
| Interventions | Istradefylline (KW-6002) |
| Enrollment | 325 |
| Start date | Mar 1, 2002 |
| Primary completion | Oct 1, 2003 |
| Completion | Oct 1, 2003 |
| First posted | Apr 5, 2007 |
| Last update posted | Apr 25, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: